JPI-547
Sponsors
Onconic Therapeutics Inc.
Conditions
Advanced Solid TumorsGastric Cancer (GC)Healthy VolunteersOvarian CancerPancreatic Ductal Adenocarcinoma
Phase 1
A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
CompletedNCT04335604
Start: 2017-12-06End: 2021-12-14Updated: 2022-06-03
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
RecruitingNCT05257993
Start: 2022-03-30End: 2030-04-01Target: 71Updated: 2026-04-13
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Not yet recruitingNCT07364422
Start: 2026-02-27End: 2029-02-28Target: 49Updated: 2026-01-23
Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants
Not yet recruitingNCT07570186
Start: 2026-05-01End: 2026-07-01Target: 36Updated: 2026-05-06
Phase 2
A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
Active, not recruitingNCT05475184
Start: 2022-08-31End: 2025-06-30Target: 58Updated: 2024-08-27
To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer
Not yet recruitingNCT07370818
Start: 2026-02-27End: 2031-12-31Target: 81Updated: 2026-01-27